Intrexon | XON - Net Income


Intrexon reported $-20.32M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Agenus USD 39.17M 49.8M Mar/2026
Alaunos Therapeutics USD -952K 54K Jun/2026
Amgen USD 3.86B 1.49B Sep/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 3.12B 610M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD -784.8M 1.37B Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD -28.48M 76.99M Sep/2026
MacroGenics USD 19.52M 56.29M Jun/2026
MannKind USD -19.03M 2.41M Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Thermo Fisher Scientific USD 1.72B 15M Sep/2026
Veracyte USD 31.5M 6.01M Sep/2026
Xencor USD -21.73M 107.19M Jun/2026